Principal U.S. Large-Cap Multi-Factor ETF logo

Principal U.S. Large-Cap Multi-Factor ETF (PLC)

Delisted
5 Jan 2021
NASDAQ (NGS) NASDAQ (NGS)
$
30. 13
0
0%
$
623.57M Market Cap
- P/E Ratio
2% Div Yield
0 Volume
- Eps
$ 30.13
Previous Close
Day Range
30.13 30.13
Year Range
18.95 30.49
Want to track PLC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Flutter Entertainment PLC Completes Repricing of 2030 Term Loan

Flutter Entertainment PLC Completes Repricing of 2030 Term Loan

DUBLIN, IRELAND and TORONTO, ON and NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Flutter Entertainment (NYSE:FLUT)(LSE:FLTR) ("Flutter"), the world's leading online sports betting and iGaming operator today announces that it has successfully completed a repricing of approximately $3.885 billion of its Term Loan B issued in November 2023 due 2030 ("Term Loan"). The repricing reduces the applicable interest rate on the Term Loan by 25 basis points from Secured Overnight Financing Rate ("SOFR") plus 2.00% to SOFR plus 1.75%.

Accesswire | 1 year ago
Hemogenyx Pharmaceuticals PLC Announces Ultrafast CAR-T Manufacturing

Hemogenyx Pharmaceuticals PLC Announces Ultrafast CAR-T Manufacturing

Collaboration with Kure.ai to develop ultrafast CAR-T manufacturing process for Hemogenyx Pharmaceuticals' AML Treatment LONDON, UNITED KINGDOM / ACCESSWIRE / December 19, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical company developing innovative therapies for blood malignancies, and Kure.ai ("Kure"), a leader in ultrafast CAR-T manufacturing technology, are pleased to announce a strategic collaboration to advance the production of CAR-T cell therapies for acute myeloid leukemia (AML) and a subset of acute lymphoblastic leukemia (ALL). This partnership aims to integrate Kure's ultrafast manufacturing (UM) technology with Hemogenyx Pharmaceuticals's proprietary CAR-T therapy, HG-CT-1 (formerly known as HEMO-CAR-T) to enable faster, more efficient production of CAR-T cells, significantly reducing manufacturing timelines while maintaining therapeutic potency.

Accesswire | 1 year ago
InterContinental Hotels Group PLC Announces Transaction in Own Shares - December 19

InterContinental Hotels Group PLC Announces Transaction in Own Shares - December 19

LONDON, UNITED KINGDOM / ACCESSWIRE / December 19, 2024 / The Company announces that on 18 December 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.

Accesswire | 1 year ago
Guardian Metal Resources PLC Announces Tempiute Mine & Mill Project Due Diligence Update

Guardian Metal Resources PLC Announces Tempiute Mine & Mill Project Due Diligence Update

LONDON, UNITED KINGDOM / ACCESSWIRE / December 18, 2024 / Guardian Metal Resources plc (LON:GMET)(OTCQX:GMTLF), a strategic development and mineral exploration company focused in Nevada, USA, provides a due diligence update regarding the binding letter of intent ("LOI" or the "Agreement") signed with Hinkinite Resources LLC ("Hinkinite" or the "Optionor") for the acquisition of the Tempiute Tungsten Mine & Mill ("Tempiute" or the "Project") announced on 31 October 2024. Tempiute, also formerly known as the Emerson Tungsten or Black Dog Mine, is located in south-central Nevada less than 240 km north of Las Vegas.

Accesswire | 1 year ago
InterContinental Hotels Group PLC Announces Transaction in Own Shares - December 18

InterContinental Hotels Group PLC Announces Transaction in Own Shares - December 18

LONDON, UNITED KINGDOM / ACCESSWIRE / December 18, 2024 / The Company announces that on 17 December 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.

Accesswire | 1 year ago
InterContinental Hotels Group PLC Announces Transaction in Own Shares - December 17

InterContinental Hotels Group PLC Announces Transaction in Own Shares - December 17

Purchase of own shares LONDON, UK / ACCESSWIRE / December 17, 2024 / The Company announces that on 16 December 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.

Accesswire | 1 year ago
InterContinental Hotels Group PLC Announces Transaction in Own Shares - December 16

InterContinental Hotels Group PLC Announces Transaction in Own Shares - December 16

Purchase of own shares LONDON, UNITED KINGDOM / ACCESSWIRE / December 16, 2024 / InterContinental Hotels Group PLC (the Company) (NYSE:IHG)(LSE:IHG)(OTC PINK:ICHGF) The Company announces that on 13 December 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.

Accesswire | 1 year ago
Angle PLC Announces HER2 Presentation at SABCS

Angle PLC Announces HER2 Presentation at SABCS

WEILL CORNELL MEDICINE PRESENTS HER2 PARSORTIX WORKFLOW AT SAN ANTONIO BREAST CANCER SYMPOSIUM Independent findings support ANGLE's HER2 assay development programme Potential for stratification of breast cancer patients for treatment with HER2 antibody drug conjugates SURREY, UK / ACCESSWIRE / December 13, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the presentation of an independent study, reporting on a novel, Parsortix®-based human epidermal growth factor receptor 2 (HER2) workflow at the prominent San Antonio Breast Cancer Symposium being held from 10 to 13 December 2024. The findings, published by Weill Cornell Medicine, corroborate ANGLE's own findings from its HER2 assay development programme, and provide a semi-automated solution which may help to accelerate adoption of CTC-based HER2 tests.

Accesswire | 1 year ago
Ecora Resources PLC Announces Portfolio Update

Ecora Resources PLC Announces Portfolio Update

LONDON, UK / ACCESSWIRE / December 12, 2024 / Ecora Resources PLC (LSE:ECOR)(TSX:ECOR), the leading royalty company focused on supporting the supply of commodities essential to creating a sustainable future, issues a portfolio update following recent updates from the operators of key projects in Ecora's royalty and stream portfolio. Corporate On 4 December, FTSE Russell announced that Ecora Resources will be included in the FTSE UK SmallCap Index and the FTSE UK All-Share Index.

Accesswire | 1 year ago
InterContinental Hotels Group PLC Announces Transaction in Own Shares - December 11

InterContinental Hotels Group PLC Announces Transaction in Own Shares - December 11

Purchase of own shares LONDON, UK / ACCESSWIRE / December 11, 2024 / The Company announces that on 10 December 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.

Accesswire | 1 year ago
Guardian Metal Resources PLC Announces Agreement to Purchase Pilot Mountain Water Rights

Guardian Metal Resources PLC Announces Agreement to Purchase Pilot Mountain Water Rights

Guardian Metal Progresses Towards its Goal to Develop Tungsten Production in the USA LONDON, UNITED KINGDOM / ACCESSWIRE / December 11, 2024 / Guardian Metal Resources plc (AIM:GMET)(OTCQX:GMTLF), a mineral exploration company focused on tungsten within Nevada, USA, announces an important update regarding its 100% owned flagship Pilot Mountain Project ("Pilot Mountain" or the "Project") located in the Walker Lane Mineral Belt in Nevada, USA. The purchase of water rights marks a pivotal Project milestone as we progress toward our goal of supporting domestic U.S. production of tungsten, which is a critical industrial and military metal essential to national security, and reinforces the Company's commitment to rapidly advancing its projects within the USA.

Accesswire | 1 year ago
Hemogenyx Pharmaceuticals PLC Announces Admission of New Ordinary Shares and New ISIN

Hemogenyx Pharmaceuticals PLC Announces Admission of New Ordinary Shares and New ISIN

Admission of New Ordinary Shares and New ISIN LONDON, UNITED KINGDOM / ACCESSWIRE / December 10, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO), the biopharmaceutical company developing innovative therapies for blood diseases, wishes to provide a further update on the admission of the New Ordinary Shares (as defined below) further to the passing of all resolutions at its Extraordinary General Meeting (the "Meeting") held on 9 December 2024. At the Meeting, resolutions were passed to approve the subdivision and reclassification of the Company's existing 1,401,815,988 ordinary shares (the "Existing Ordinary Shares") by 1:2 so that each Existing Ordinary Share was subdivided and reclassified into 1 new ordinary share of £0.000025 each (the "New Ordinary Shares") and 1 deferred share of £0.009975 each (the "Deferred Shares"), followed by a consolidation of the New Ordinary Shares by 400:1 so that every 400 New Ordinary Shares were consolidated into 1 New Ordinary Share of £0.01 each (the "Capital Reorganisation").

Accesswire | 1 year ago
Loading...
Load More